Overview

Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective: - To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer. Secondary Objective: - To determine the nature and degree of toxicity of the combination of gemcitabine and cisplatin in this cohort of patients.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Cisplatin
Gemcitabine